A5024400795- Thyroid Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Thyroid and Parathyroid Surgery
- S100 Proteins and Annexins
- Thyroid Disorders and Treatments
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Cancer-related Molecular Pathways
- Hormonal Regulation and Hypertension
- Neuroendocrine Tumor Research Advances
- Ovarian cancer diagnosis and treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Bioinformatics and Genomic Networks
- Head and Neck Anomalies
- Cancer, Hypoxia, and Metabolism
- Radiation Dose and Imaging
- Cancer, Lipids, and Metabolism
- Nutrition, Genetics, and Disease
- Multiple and Secondary Primary Cancers
- Gene expression and cancer classification
- Adrenal and Paraganglionic Tumors
- Pituitary Gland Disorders and Treatments
- Connective Tissue Growth Factor Research
- Parathyroid Disorders and Treatments
The Maria Sklodowska-Curie National Research Institute of Oncology
2016-2025
Centrum Onkologii
2001-2022
Center For Reconstructive Urethral Surgery
2020
Qingdao University
2018
Johns Hopkins University
2014-2018
Affiliated Hospital of Qingdao University
2018
Istituto Oncologico Veneto
2017
Istituti di Ricovero e Cura a Carattere Scientifico
2017
University of Pisa
2017
University of Perugia
2017
BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role PTC-related patient mortality has not been established.To investigate the relationship between mutation and mortality.Retrospective study of 1849 patients (1411 women 438 men) with median age 46 years (interquartile range, 34-58 years) an overall follow-up time 33 months 13-67 months) after initial treatment at 13 centers 7 countries 1978 2011.Patient deaths specifically caused by PTC.Overall, was 5.3%...
Purpose To investigate the prognostic value of BRAF V600E mutation for recurrence papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter study relationship between PTC in 2,099 patients (1,615 women 484 men), with median age 45 years (interquartile range [IQR], 34 to 58 years) follow-up time 36 months (IQR, 14 75 months). Results The overall prevalence 48.5% (1,017 2,099). occurred 20.9% (213 1,017) mutation–positive 11.6% (125 1,082) mutation–negative...
Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support.This study sought establish the clinicopathological risk major variants: conventional (CPTC), follicular-variant (FVPTC), and tall-cell (TCPTC).This was retrospective outcomes 6282 patients (4799 females 1483 males) from 26 centers The Cancer Genome Atlas...
The growing detection of papillary thyroid microcarcinomas (PTMCs) is paralleled by an increase in surgical procedures. Due to the frequent indolent nature, cost, and risk surgery, active surveillance (AS) ultrasound-guided minimally invasive treatments (MITs) are suitable cases incidental PTMC proposed as alternatives thyroidectomy. Surgery radioiodine established for relapsing cervical differentiated carcinoma (DTC) metastases. But refractoriness, complications, adverse influence on...
With the widespread use of sensitive imaging techniques, which include neck visualization, a conspicuous number thyroid nodules emerge and demand attention. Most lesions are benign, asymptomatic, do not warrant treatment. In case cancer diagnosis, most small, intrathyroidal indolent neoplasms that can safely be managed conservatively. There is pronounced need for more cost-effective, risk-adapted approaches to management this highly prevalent condition, taking wishes patient into...
At present, no European recommendations for the management of pediatric thyroid nodules and differentiated carcinoma (DTC) exist. Differences in clinical, molecular, pathological characteristics between adult DTC emphasize need specific population. An expert panel was instituted by executive committee Thyroid Association including an international community experts from a variety disciplines endocrinology, pathology, endocrine surgery, nuclear medicine, clinical genetics, oncology. The 2015...
Abstract The study looked for an optimal set of genes differentiating between papillary thyroid cancer (PTC) and normal tissue assessed the sources variability in gene expression profiles. analysis was done by oligonucleotide microarrays (GeneChip HG-U133A) 50 samples taken intraoperatively from 33 patients (23 PTC 10 with other disease). In initial group 16 samples, we profile singular value decomposition which specified three major patterns variability. first most distinct mode grouped...
Purpose For the past 65 years, patient age at diagnosis has been widely used as a major mortality risk factor in stratification of papillary thyroid cancer (PTC), but whether this is generally applicable, particularly patients with different BRAF genetic backgrounds, unclear. The current study was designed to test factor. Patients and Methods We conducted comparative relationship between PTC-specific respect status 2,638 (623 men 2,015 women) median 46 years (interquartile range, 35 58...
Multifocality is often treated as a risk factor for papillary thyroid cancer (PTC), prompting aggressive treatments, but its prognostic value remains unestablished. To investigate the role of tumor multifocality in clinical outcomes PTC. Multicenter study relationship between and PTC 2638 patients (623 men 2015 women) with median [interquartile range (IQR)] age 46 (35 to 58) years (IQR) follow-up time 58 (26 107) months at 11 medical centers six countries. Surveillance, Epidemiology End...
The guidelines Thyroid Cancer 2022 are prepared based on previous Polish recommendations updated in 2018. They consider international - American Association (ATA) 2015 and National Comprehensive Network (NCCN); however, they adapted according to the ADAPTE process. strength of quality scientific evidence assessed GRADE system ATA NCCN recommendations. core changes made is inclusion results those studies that have already proven themselves prospectively. These extensions allow de-escalation...
Precise risk stratification-based treatment of solitary intrathyroidal papillary thyroid cancer (SI-PTC) that is larger than 1.0 cm and 4.0 or less undefined.
How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined.To study whether LNM-associated PTC.We retrospectively analyzed the effect of LNM on PTC-specific with respect to status 2638 patients (2015 females and 623 males) from 11 centers 6 countries, median age 46 [interquartile range (IQR) 35-58] years follow-up time 58 (IQR 26-107) months.Overall, showed a modest wild-type but strong one patients. In conventional...
Purpose To test whether the prognostic risk of male sex in papillary thyroid cancer (PTC) is determined by BRAF V600E and can thus be stratified status. Patients Methods We retrospectively investigated relationship between clinicopathologic outcomes PTC, particularly mortality, with respect to status 2,638 patients (male, n = 623; female, 2,015) from 11 centers six countries, median age 46 years (interquartile range, 35-58 years) at diagnosis follow-up time 58 months 26-107 months). Results...
Significant advances have been made in thyroid cancer research recent years, therefore relevant clinical guidelines need to be updated. The current Polish "Diagnostics and Treatment of Thyroid Carcinoma" formulated at the "Thyroid Cancer Other Malignancies Endocrine Glands" conference held Wisła November 2015 [1].
The oral cancer treatment of choice is surgical excision with an organ preservation, if it possible. Radiation therapy commonly used as a postoperative treatment. Delivering radiation dose during surgery, defined intraoperative radiotherapy (IORT), can be very useful especially in case high risk recurrence or where gross macroscopic residual disease are present. aim this retrospective study to evaluate the effectiveness IORT combined fractionated irradiation (EBRT) patients squamous cell...
Background The molecular mechanisms driving the papillary thyroid carcinoma (PTC) are still poorly understood. most frequent genetic alteration in PTC is BRAFV600E mutation–its impact may extend even beyond genomic profile and influence tumor characteristics clinical behavior. Methods In order to identify BRAF-dependent signature of early carcinogenesis PTC, a transgenic mouse model with BRAFV600E-induced was developed. Mice samples were used microarray analysis data referred human dataset....
The molecular etiology of follicular thyroid tumors is largely unknown, rendering the diagnostics these challenging. somatic alterations present in apart from RAS gene mutations and PAX8/PPARG translocations are not well described. To evaluate profile alteration tumors, a total 82 tissue samples derived 48 patients were subjected to targeted Illumina HiSeq next generation sequencing 372 cancer-related genes. New identified oncogenes (MDM2, FLI1), transcription factors repressors (MITF, FLI1,...
In recent years well-recognized scientific societies introduced guidelines for ultrasound (US) malignancy risk stratification of thyroid nodules. These categorize the in relation to a combination several US features. Based on these image lexicons an US-based computer-aided diagnosis (CAD) systems were developed. Nevertheless, their clinical utility has not been evaluated any study surgeon-performed office thyroid. Hence, aim this pilot was validate s-DetectTM mode semi-automated...
Introduction The risk of over-treatment in low-advanced PTC stages has prompted clinicians to search for new reliable prognostic factors. presence BRAF mutation, the most frequent molecular event PTC, seems be a good candidate. However, there is still lack randomised trials and its significance been proved by retrospective analyses, involving large group patients. question arises whether this factor useful smaller populations, characterised specialised centres. Thus, aim study was evaluate...